Michael Untch

Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto

M. Rezai, P. Fasching, A. Schneeweiss, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.

P. Fasching, A. Schneeweiss, C. Denkert, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study.

C. Denkert, W. Eiermann, F. Marmé, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

S. Loi, V. Nekljudova, C. Schem, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial

P. Fasching, T. Fehm, S. Loibl, 2011, British Journal of Cancer.

Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial).

D. Amadori, A. Musolino, L. Cavanna, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy.

V. Nekljudova, S. Darb-Esfahani, S. Loibl, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.